BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24148218)

  • 1. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
    Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
    Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
    Inthachai T; Lekawanvijit S; Kumfu S; Apaijai N; Pongkan W; Chattipakorn SC; Chattipakorn N
    Exp Physiol; 2015 Jun; 100(6):667-79. PubMed ID: 25823534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
    Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model.
    Al-Awar A; Almási N; Szabó R; Takacs I; Murlasits Z; Szűcs G; Török S; Pósa A; Varga C; Kupai K
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
    Yin M; Silljé HH; Meissner M; van Gilst WH; de Boer RA
    Cardiovasc Diabetol; 2011 Sep; 10():85. PubMed ID: 21955567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
    Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
    PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
    Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
    Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart.
    Chinda K; Sanit J; Chattipakorn S; Chattipakorn N
    Diab Vasc Dis Res; 2014 Mar; 11(2):75-83. PubMed ID: 24357666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
    Irons BK; Weis JM; Stapleton MR; Edwards KL
    Curr Diabetes Rev; 2012 May; 8(3):169-82. PubMed ID: 22429011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
    Jackson EK; Mi Z; Tofovic SP; Gillespie DG
    Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats.
    Sivasinprasasn S; Tanajak P; Pongkan W; Pratchayasakul W; Chattipakorn SC; Chattipakorn N
    Sci Rep; 2017 Mar; 7():44306. PubMed ID: 28281660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.